22:23 , Apr 22, 2019 |  BC Extra  |  Financial News

Poseida postpones IPO in favor of $142M series C

Poseida raised a $142 million series C round Monday that includes a $75 million contribution from Novartis AG (NYSE:NVS; SIX:NOVN). CEO Eric Ostertag told BioCentury that Poseida Therapeutics Inc. (San Diego, Calif.) has withdrawn the...
16:51 , Apr 22, 2019 |  BioCentury  |  Finance

Poseida's sea change

Rather than execute the IPO it proposed in January, Poseida has instead raised a $142 million series C round that includes a $75 million contribution from Novartis. CEO Eric Ostertag told BioCentury that Poseida has...
21:03 , Jan 30, 2019 |  BC Innovations  |  Translation in Brief

Epigenetic links in endometriosis

An HDAC3-mediated epigenetic pathway could lead to new therapies and markers for endometriosis and associated infertility. Researchers from Michigan State University and Yonsei University College of Medicine have linked an epigenetic pathway involving HDAC3 to...
00:26 , Jan 25, 2019 |  BC Week In Review  |  Financial News

BridgeBio raises $299M to advance rare disease portfolio

BridgeBio Pharma LLC (Palo Alto, Calif.) said it raised $299.2 million on Jan. 23 in a venture round to develop compounds for rare genetic diseases. The company in-licenses preclinical and clinical stage assets from academia...
23:35 , Jan 23, 2019 |  BC Extra  |  Financial News

BridgeBio raises $299M to advance rare disease portfolio

BridgeBio Pharma LLC (Palo Alto, Calif.) said it raised $299.2 million on Wednesday in a venture round to develop compounds for rare genetic diseases. The company in-licenses preclinical and clinical stage assets from academia and...
01:19 , Oct 6, 2018 |  BioCentury  |  Finance

In sight of uncharted territory

Strong growth from small- and mid-caps coupled with a late run from large cap biotechs has pushed the sector within sight of its all-time high in 2015. Some buysiders now are seeing red flags of...
00:48 , Oct 6, 2018 |  BioCentury  |  Finance

Seeking validation

The final stretch of the year offers clinical catalysts and early launch data that could validate investments in hot immuno-oncology targets and large untapped markets. Late-stage readouts from Vertex Pharmaceuticals Inc. in cystic fibrosis and...
23:56 , Sep 28, 2018 |  BioCentury  |  Finance

Paper chase

Even before this week’s spate of IPOs, this year’s class of newly public biotechs on NASDAQ had surpassed that of 2017 in terms of funds raised, leaving this year’s class within striking distance of 2015’s...
22:15 , Sep 21, 2018 |  BC Extra  |  Clinical News

GTx shares crater after incontinence readout

GTx Inc. (NASDAQ:GTXI) shed 92% of its value Friday, falling from the small cap band to trading at roughly the value of its cash, after the company's enobosarm (GTx-024) failed in the Phase II ASTRID...
16:29 , Sep 21, 2018 |  BC Week In Review  |  Financial News

Ahead of Phase III mucositis study, Galera raises $150M

Galera Therapeutics Inc. (Malvern, Pa.) raised a combined $150 million in a $70 million series C round and $80 million royalty deal led by new investor Clarus. The fund-raising comes ahead of Galera's planned Phase...